Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis

Journal of Periodontal Research

Volumn 41, Issue 4, 2006, Pages 354-360

  Lu, H K ^a,b   Chen, Y L ^b   Chang, H C ^a   Li, C L ^a   Kuo, M Y P ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Interteukin 6; Oncostatin M; Osteoprotegerin; Receptor activator of nuclear factor kappa B ligand

Indexed keywords

CARRIER PROTEIN; CELL RECEPTOR; CYTOKINE; GLYCOPROTEIN; INTERLEUKIN 6; MEMBRANE PROTEIN; ONCOSTATIN M; OSM PROTEIN, HUMAN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; FEMALE; GINGIVA; GINGIVITIS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PERIODONTICS; PERIODONTITIS;

ADULT; ANALYSIS OF VARIANCE; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHRONIC DISEASE; CYTOKINES; FEMALE; GINGIVA; GINGIVAL CREVICULAR FLUID; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; ONCOSTATIN M; OSTEOPROTEGERIN; PERIODONTAL INDEX; PERIODONTITIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; STATISTICS, NONPARAMETRIC;

EID: 33748549017     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2006.00883.x     Document Type: Article

References (31)

1. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055.
2. Anderson MA, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179.
3. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced byosteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96:3540-3545.
4. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
5. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
6. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337.
7. Teng YT, Nguyen H, Gao X et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106:59-67.
8. Liu D, Xu JK, Figliomeni L et al. Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. Int J Mol Med 2003;11:17-21.
9. Mogi M, Otogoto N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-169.
10. Modur V, Feldbaus MJ, Weyrich AS et al. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 1997;100:158-168.
11. Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthr Rheum 2000;43:281-288.
12. Brown TJ, Rowe JM, Liu JW, Shoyab M. Regulation of IL-6 expression by oncostatin M. J Immunol 1991;147:2I75-2180.
13. Lin S-J, Chen Y-L, Kuo MY-P, Li C-L, Lu H-K. Measurement of gp130 cytokine oncostatin M and IL-6 in gingival cervicular fluid of patients with chronic periodontitis. Cytokine 2005;30:160-167.
14. Joss A, Adler R, Lang NP. Bleeding on probing. A parameter for monitoring periodontal conditions in clinical practice. J Clin Periodontol 1994;21:402-408.
15. Uematsu S, Mogi M, Deguchi T. Interleukin (IL)-1β, IL-6, tumor necrosis factor-α, epidermal growth factor, and β2-microglobulin levels are elevated in gingival crevicular fluid during human orthodontic tooth movement. J Dent Res 1996;75:562-567.
16. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin m, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine 2000;12:613-621.
17. Jay PR, Centrella M, Lorenzo J, Bruce AG, Horowitz MC. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption. Endocrinology 1996;137:1151-1158.
18. Taguchi Y, Yamamoto M, Yamate T et al. Interleukin-6-type cytokines stimulates mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 1998;110:559-574.
19. Holt I, Davie MWJ, Marshall MJ. Osteoclasts are not the major source of interleukin-6 in mouse parietal bone. Bone 1996;18:221-226.
20. Udagawa N, Takahashi N, Katagiri T et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 1995;182:1461-1468.
21. Bellido T, Stahl N, Farruggella TJ, Borba GD, Yancopuolos GD, Manolagas SC. Detection of receptors for interleukin-6, interleukin-11, leukaemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/ osteoblastic cells. J Clin Invest 1996;97:431-437.
22. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 1999;77:188-193.
23. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclasto-genesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
24. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 2000;21:495-502.
25. Nakashima T, Kobayashi Y, Yamasaki S et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775.
26. Lacey DL, Timms E, Tan HL et al Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
27. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
28. Crotti T, Smith MD, Hirsch R et al. Receptor activator NF KB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. Receptor activator NF KB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodont Res 2003;38:380-387.
29. Dhore CR, Cleutjens JP, Lutgens E et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
30. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-637.
31. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.